ATLASense Biomed Overview
ATLASense is addressing healthcare’s most significant and growing challenge: transitioning care from hospitals to homes safely and cost-effectively while preventing life-threatening events. Introducing REPHAEL: the world’s first wearable platform delivering ICU-level monitoring and predictive insights anywhere—hospital, home, or on the go. REPHAEL isn’t just a monitor; it PREDICTS, detects, and alerts healthcare teams to critical risks like respiratory failure, sepsis, heart failure, and falls—days before they escalate. By enabling SAFE, informed clinical decisions remotely ensure hospital-level care at home. REPHAEL allows ICU-Grade Precision: Continuous, comprehensive monitoring powered by proprietary sensors and AI-driven insights. Its economical advantage: A reusable device that serves multiple patients with various morbidities, offering the lowest cost of use compared to any alternative. Enabling SAFE Decisions: Provides doctors with actionable, predictive data.
Cumulative Funding Raised Over Time ($)
$1.0MAug 2022
$1.1MJan 2020
$2.1MJan 2021
Latest News
growth-positive
ATLASense Biomed Revolutionizes Remote Health Monitoring with REPHAEL Platform
ATLASense Biomed is showcasing its advanced remote monitoring solution, the REPHAEL platform, at the Medica Trade Fair. This platform offers ICU-grade monitoring capabilities beyond hospital settings, using a wearable device and cloud-based analytics for real-time health management. The AI-powered system provides continuous monitoring and early detection of critical conditions such as cardiac distress and sepsis. With Medicare reimbursement and FDA submission underway, the REPHAEL platform is positioned as a cost-effective, transformative solution in healthcare. ATLASense aims to enhance patient outcomes and reduce healthcare costs by making high-quality monitoring accessible in various settings.
Product Stage
growth-positive
ATLASense Biomed Unveils REPHAEL Platform: A New Era in Remote Health Monitoring
ATLASense Biomed is revolutionizing remote health surveillance with its REPHAEL Platform, an AI-powered system that provides early warning alerts for critical conditions like ARDS and sepsis. The platform is designed to enhance patient care in both hospital and home settings by offering predictive insights that help prevent patient deterioration. Recognized for its innovation, ATLASense has received accolades for the REPHAEL Platforms effectiveness. The company is expanding the platforms capabilities to address a broader range of health issues, aiming to improve patient outcomes and reduce healthcare costs globally.
growth-positive
ATLASense Biomed Earns Henry Ford Health System's Global Health Tech Challenge Top Prize - JLM-BioCity
ATLASense Biomed, an Israeli-based start-up company, has won the 2020 Henry Ford Health Systems Global Health Tech Challenge for their patient monitoring system that uses predictive analytics. The company will receive up to $75,000 to further develop their technology at Henry Ford. The monitoring system has the potential to improve efficiency in hospitals and patient care. The challenge aims to identify advanced healthcare technology from Israel and launch them in the US healthcare market. ATLASense Biomeds technology uses a patch sensor placed on the patients chest to monitor physiological changes and alert staff in real-time when intervention is needed. The company believes their system has the potential to become a new standard of care in the United States.
Partners
growth-positive
Patient Monitoring System Earns Top Prize in Henry Ford's Global Health Tech Challenge
Israeli start-up ATLASense Biomed has won Henry Ford Health Systems Global Health Tech Challenge for its patient monitoring system. The company will receive up to $75,000 to further research and develop its technology at Henry Ford. The monitoring system uses predictive analytics to flag real-time physiological changes in the body before, during, and after surgery. It has the potential to improve efficiency at hospitals and patient care. The technology uses a patch sensor placed on the patients chest to monitor various physiological changes, and with predictive analysis, it can alert staff when immediate intervention is needed. The goal is to develop real-time physiological monitors that can communicate directly with the electronic medical record.
PartnersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $2.81M |
| Last funding | $300K |
| Stage | Seed |
| Rounds | 6 |
| Investors | 0 |
Team Members
9
Employees: 11-50
Web & Social Links
| Website | atlasensebiomed.com |
| Careers | Careers page |
Locations
Ezer Weizman Street 1, Hod Hasharon, Israel
734 Clarence Avenue, Oak Park, IL, USA
Photos & Videos
12 item(s)
ATLASense Biomed Business
Business models
B2B2C, B2B
Product stage
Beta
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcarePatient Remote MonitoringTarget Customer
Healthcare & Life SciencesHealthcareProvidersInsurance CompaniesCore Technology
Artificial IntelligenceMachine LearningSensingCommunicationsIOTTags (45)
surgeonswomendoctorsparentshospitalsremote-monitoringsensorsrespiratorycardiologyecgwearablepredictive-analyticsdata-analyticsheart-failureblood-pressuredecision-makingphysiological-parametershome-caredigital-healthcareseniorshealthcare-providerspreventiontelemedicinereal-timeiotinsurance-companiespatientspharma-companieschronic-patientsbig-datadiagnosticsmhealthsmart-mobilitymachine-learningmonitoringpersonalizationartificial-intelligenceservice-providersdriver-safetyvital-signsmedical-technologiesnon-invasiveclinicsmedical-device-manufacturersinvestorsGeographic Markets
AsiaAfricaIsraelBrazilGlobalIndiaUnited StatesEuropeATLASense Biomed Financials
$2.81M
Total funding
Undisclosed
Capital raised
$300K
Last funding
Seed
Funding stage
6
Total rounds
0
Investors
Cumulative Funding Raised Over Time ($)
$1.0MAug 2022
$1.1MJan 2020
$2.1MJan 2021
Private Equity Funding
Seed
Aug 2022
$1M
Seed
Jan 2021
$1M
Pre-Seed
Jan 2020
$100K
Non-Equity Funding
GrantEvent
Dec 2023
$300K
GrantEvent
Sep 2021
$75K
GrantEvent
Jan 2020
$335K
ATLASense Biomed Lifecycle
Cumulative Funding Raised Over Time
$1.0MAug 2022
$1.1MJan 2020
$2.1MJan 2021
All Events
Seed
Aug 2022
$1M
Seed
Jan 2021
$1M
Pre-Seed
Jan 2020
$100K
GrantEvent
Dec 2023
$300K
GrantEvent
Sep 2021
$75K
GrantEvent
Jan 2020
$335K
ATLASense Biomed News
4 articles
growth-positive
ATLASense Biomed Revolutionizes Remote Health Monitoring with REPHAEL Platform
ATLASense Biomed is showcasing its advanced remote monitoring solution, the REPHAEL platform, at the Medica Trade Fair. This platform offers ICU-grade monitoring capabilities beyond hospital settings, using a wearable device and cloud-based analytics for real-time health management. The AI-powered system provides continuous monitoring and early detection of critical conditions such as cardiac distress and sepsis. With Medicare reimbursement and FDA submission underway, the REPHAEL platform is positioned as a cost-effective, transformative solution in healthcare. ATLASense aims to enhance patient outcomes and reduce healthcare costs by making high-quality monitoring accessible in various settings.
Product Stage
growth-positive
ATLASense Biomed Unveils REPHAEL Platform: A New Era in Remote Health Monitoring
ATLASense Biomed is revolutionizing remote health surveillance with its REPHAEL Platform, an AI-powered system that provides early warning alerts for critical conditions like ARDS and sepsis. The platform is designed to enhance patient care in both hospital and home settings by offering predictive insights that help prevent patient deterioration. Recognized for its innovation, ATLASense has received accolades for the REPHAEL Platforms effectiveness. The company is expanding the platforms capabilities to address a broader range of health issues, aiming to improve patient outcomes and reduce healthcare costs globally.
growth-positive
ATLASense Biomed Earns Henry Ford Health System's Global Health Tech Challenge Top Prize - JLM-BioCity
ATLASense Biomed, an Israeli-based start-up company, has won the 2020 Henry Ford Health Systems Global Health Tech Challenge for their patient monitoring system that uses predictive analytics. The company will receive up to $75,000 to further develop their technology at Henry Ford. The monitoring system has the potential to improve efficiency in hospitals and patient care. The challenge aims to identify advanced healthcare technology from Israel and launch them in the US healthcare market. ATLASense Biomeds technology uses a patch sensor placed on the patients chest to monitor physiological changes and alert staff in real-time when intervention is needed. The company believes their system has the potential to become a new standard of care in the United States.
Partners
growth-positive
Patient Monitoring System Earns Top Prize in Henry Ford's Global Health Tech Challenge
Israeli start-up ATLASense Biomed has won Henry Ford Health Systems Global Health Tech Challenge for its patient monitoring system. The company will receive up to $75,000 to further research and develop its technology at Henry Ford. The monitoring system uses predictive analytics to flag real-time physiological changes in the body before, during, and after surgery. It has the potential to improve efficiency at hospitals and patient care. The technology uses a patch sensor placed on the patients chest to monitor various physiological changes, and with predictive analysis, it can alert staff when immediate intervention is needed. The goal is to develop real-time physiological monitors that can communicate directly with the electronic medical record.
PartnersInvestment
ATLASense Biomed Team
Shimon Yisraelian
Head of Polymonitor Development
Ditza Gross
Director of The Pulmonary Rehabilitation Unit at Tel Aviv Medical Center
Alex Weiman
QA
Allon Rothfarb
Senior Programmer
Employee Info
| Employees (range) | 11-50 |
| Exact count | 12 |
| Team members | 10 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.
ATLASense Biomed Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 99/100 |
| Missing | markets |
| BI Verification | Natalia Golczar |
| Registrar ID | 515261386 |
| Crunchbase | atlasense-biomed |
| Phone | +972547706688 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-12-14T00:00:00.000Z |
| Created | 2014-10-19T00:00:00.000Z |
| Claimed | Yes |